“We are delighted with the robust sales growth in the third quarter, during which we have continued to increase commercial capacity and deliver CARVYKTI to more multiple myeloma patients around the ...

Legend Biotech (NASDAQ:LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.57 and the consensus Revenue Estimate is $146 ...

Legend has become a force partnering with Johnson & Johnson on CAR-T multiple myeloma therapy Carvykti. Thanks to an FDA approval in second-line multiple myeloma, Carvykti’s sales, as booked by J&J, ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a ...

Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI therapy, featured at the American Society of Hematology meeting, ...